SHAREme.

Scientific Hub of Applied Research in Emerging Medical science & technology

Received: 02.06.2026 Revised: 28.06.2026 Accepted: 30.06.2026

check for updates

Review Article

Microencapsulation in CNS Drug Delivery Systems: Recent Advances and Future Perspectives

M.Shunmuga Sundaram[1]* , Anju.C.L[2], Kannan Raman[3]

[1]Department of Pharmaceutics, The dale view college of pharmacy and research center, Punalal 695575, Thiruvananthapuram, Kerala, India.

[2]Department of Pharmaceutics, Kerala academy of pharmacy, Kandala 695512, Kattakada, Thiruvananthapuram, Kerala, India.

[3]Department of Pharmacology, St.Johns College of Pharmaceutical Sciences and Research, Kattappana, Idukki-685515. Kerala, India.

Corresponding Author: **M.Shunmuga Sundaram***
Mail id: unitedsundar18@gmail.com

Abstract

Central nervous system (CNS) disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, brain tumors, and psychiatric illnesses remain major healthcare challenges worldwide. Effective treatment of these disorders is often limited by the presence of the blood-brain barrier (BBB), which restricts the transport of therapeutic agents into the brain. Microencapsulation has emerged as a promising drug delivery strategy capable of improving drug stability, protecting sensitive molecules from degradation, prolonging drug release, and enhancing therapeutic efficacy. Microcapsules consist of active pharmaceutical ingredients enclosed within polymeric matrices or shell structures, enabling controlled and targeted drug delivery. Various microencapsulation techniques including solvent evaporation, spray drying, coacervation, ionic gelation, and interfacial polymerization have been employed for the development of CNS drug delivery systems. Recent advances in biodegradable polymers, nanotechnology, and stimuli-responsive materials have further enhanced the performance of microencapsulated formulations. Applications of microencapsulation have demonstrated significant potential in the treatment of Alzheimer's disease, Parkinson's disease, epilepsy, brain tumors, and depression. Despite challenges related to large-scale manufacturing, regulatory approval, and long-term safety evaluation, ongoing research continues to improve the clinical applicability of these systems. This review discusses the role of microencapsulation in CNS drug delivery, preparation methods, therapeutic applications, recent advancements, and future perspectives.

Keywords: Microencapsulation, CNS Drug Delivery, Blood-Brain Barrier, Controlled Release, Neurotherapeutics

1. Introduction

Central nervous system (CNS) disorders represent a significant global health burden, affecting millions of individuals and contributing substantially to morbidity, mortality, and healthcare expenditure [1]. Diseases such as Alzheimer's disease, Parkinson's disease, epilepsy, brain tumors, depression, and schizophrenia require effective therapeutic interventions that can deliver adequate concentrations of drugs to the brain [2]. However, successful treatment of CNS disorders remains challenging because of the highly selective blood-brain barrier (BBB), which restricts the entry of many therapeutic molecules into brain tissues [3].

The BBB is composed of tightly joined endothelial cells, astrocytes, pericytes, and basement membranes that collectively regulate molecular transport between systemic circulation and the brain [4].

While this barrier protects neural tissues from toxins and pathogens, it also limits the delivery of approximately 98% of small-molecule drugs and nearly all macromolecular therapeutics [5]. Consequently, researchers have focused on developing advanced drug delivery systems capable of overcoming these biological obstacles. Microencapsulation is one of the most promising approaches for enhancing CNS drug delivery [6].

It involves the entrapment of active pharmaceutical ingredients within polymeric matrices or membrane-coated structures that protect the drug from degradation and allow controlled release [7]. Microencapsulated systems offer several advantages including prolonged therapeutic action, reduced dosing frequency, improved drug stability, enhanced bioavailability, and minimized systemic adverse effects [8]. Recent advances in polymer science, nanotechnology, and pharmaceutical engineering have expanded the potential applications of microencapsulation in neurological disorders [9]. This review discusses the principles of microencapsulation, formulation methods, therapeutic applications, recent developments, and future prospects in CNS drug delivery.

2. Blood-Brain Barrier and Challenges in CNS Drug Delivery

The blood-brain barrier is a specialized physiological barrier that maintains brain homeostasis by regulating molecular transport between blood circulation and neural tissues [10]. Tight junction proteins such as claudins, occludins, and junctional adhesion molecules create a highly restrictive barrier against drug penetration [11].

Many CNS drugs exhibit poor permeability due to unfavorable physicochemical properties including high molecular weight, hydrophilicity, and susceptibility to efflux transporters such as P-glycoprotein [12]. Consequently, conventional drug administration often results in inadequate drug concentrations at target sites and reduced therapeutic efficacy [13].

Microencapsulation offers an effective solution by protecting drugs from premature degradation, controlling release kinetics, and enhancing transport across biological barriers [14]. The ability to modify polymer composition and surface characteristics further improves targeting efficiency and therapeutic outcomes [15].

3. Microencapsulation Technology

Microencapsulation refers to the process of surrounding active pharmaceutical ingredients with protective polymeric coatings to form microscopic particles ranging from 1 to 1000 μm [16]. Depending on structural organization, microcapsules may exist as reservoir systems containing a distinct core-shell arrangement or matrix systems where drug molecules are uniformly dispersed throughout the polymer matrix [17]. Various natural and synthetic polymers have been utilized for microencapsulation. Natural polymers such as alginate, gelatin, chitosan, and starch possess excellent biocompatibility and biodegradability [18]. Synthetic polymers including poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and polycaprolactone (PCL) offer superior mechanical properties and controlled release characteristics [19]. Microencapsulation improves drug stability, reduces toxicity, prolongs circulation time, and enables site-specific delivery [20]. These advantages make the technology particularly valuable for CNS therapeutics where sustained and targeted drug release is essential.

4. Preparation Methods of Microencapsulation

Several techniques have been developed for the preparation of microencapsulated drug delivery systems. Solvent evaporation is one of the most widely employed methods and involves dissolution of drug and polymer followed by solvent removal to produce microcapsules [21]. Spray drying is another commonly used technique due to its simplicity, scalability, and cost-effectiveness [22]. In this process, polymer-drug solutions are atomized into heated chambers where rapid solvent evaporation produces dry microparticles.

Coacervation-phase separation involves polymer precipitation around drug particles and is particularly suitable for encapsulating sensitive biomolecules [23]. Ionic gelation utilizes electrostatic interactions between oppositely charged polymers to form microcapsules under mild conditions [24]. Interfacial polymerization and emulsion-based methods are also extensively used for producing controlled-release formulations with high encapsulation efficiency [25]. Selection of an appropriate method depends on drug properties, polymer characteristics, desired release profile, and intended therapeutic application.

5. Applications of Microencapsulation in CNS Drug Delivery

Microencapsulation has demonstrated considerable potential in the management of various neurological disorders. In Alzheimer's disease, microencapsulated formulations of donepezil, rivastigmine, and

memantine have shown improved bioavailability and prolonged therapeutic action [26]. For Parkinson's disease, microencapsulation of levodopa and dopamine agonists enables sustained drug release and reduces fluctuations in plasma drug concentrations [27]. Such formulations may improve symptom control and reduce dosing frequency.

Epilepsy treatment has also benefited from microencapsulation technology. Controlled-release formulations of carbamazepine and phenytoin provide prolonged anticonvulsant activity while minimizing peak-related adverse effects [28]. In brain tumor therapy, microencapsulated chemotherapeutic agents such as temozolomide and paclitaxel facilitate localized drug delivery and improve treatment outcomes [29]. Similarly, controlled-release antidepressant formulations have shown potential for improving patient adherence and therapeutic efficacy in psychiatric disorders [30].

6. Recent Advances and Future Perspectives

Recent advances in microencapsulation technology have focused on the development of nanoparticle-loaded microcapsules, hybrid lipid-polymer systems, and stimuli-responsive formulations [31]. These systems can respond to physiological triggers such as pH, temperature, or enzyme activity to achieve site-specific drug release [32]. Nose-to-brain delivery combined with microencapsulation has emerged as a promising strategy for bypassing the BBB and improving CNS drug targeting [33]. Furthermore, advances in nanotechnology have enabled the design of multifunctional carriers capable of simultaneous imaging, diagnosis, and therapy [34]. Artificial intelligence and machine learning tools are increasingly being applied to optimize formulation design, predict release kinetics, and improve manufacturing processes [35]. These innovations are expected to accelerate clinical translation and support the development of personalized CNS therapeutics.

7. Conclusion

Microencapsulation has emerged as a highly promising strategy for overcoming challenges associated with CNS drug delivery. By enhancing drug stability, controlling release profiles, and improving bioavailability, microencapsulated systems offer significant advantages over conventional formulations. Applications in Alzheimer's disease, Parkinson's disease, epilepsy, brain tumors, and psychiatric disorders demonstrate the broad therapeutic potential of this technology. Recent developments in biodegradable polymers, nanotechnology, stimuli-responsive materials, and nose-to-brain delivery systems have further expanded its clinical relevance. Although challenges related to manufacturing scalability, regulatory approval, and long-term safety remain, continued research is expected to address these limitations. Future integration of microencapsulation with artificial intelligence and precision medicine may enable more efficient and personalized treatment approaches for CNS disorders. Therefore, microencapsulation represents an important platform for next-generation neurotherapeutics and holds considerable promise for improving patient outcomes.

DECLARATIONS: Ethics approval and consent to participate: NA

Availability of data and material: Data openly available in a public repository that issues datasets with DOIs.

Competing interest: None

Funding: NA

References

1. Pardridge WM. Drug transport across the blood-brain barrier. *Journal of Cerebral Blood Flow & Metabolism*. 2012;32(11):1959–1972. DOI: 10.1038/jcbfm.2012.126
2. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery. *Journal of Controlled Release*. 2016;235:34–47. DOI: 10.1016/j.jconrel.2016.05.044
3. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. *Neurobiology of Disease*. 2010;37(1):13–25. DOI: 10.1016/j.nbd.2009.07.030
4. Daneman R, Prat A. The blood-brain barrier. *Cold Spring Harbor Perspectives in Biology*. 2015;7(1):a020412. DOI: 10.1101/cshperspect.a020412
5. Banks WA. Characteristics of compounds that cross the blood-brain barrier. *BMC Neurology*. 2009;9(Suppl 1):S3. DOI: 10.1186/1471-2377-9-S1-S3

6. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. *International Journal of Pharmaceutics*. 2004;282(1-2):1–18. DOI: 10.1016/j.ijpharm.2004.04.013
7. Benita S. *Microencapsulation: Methods and Industrial Applications*. 2nd ed. CRC Press; 2006.
8. Singh MN, Hemant KSY, Ram M, Shivakumar HG. Microencapsulation: A promising technique for controlled drug delivery. *Research in Pharmaceutical Sciences*. 2010;5(2):65–77.
9. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. *Polymers*. 2011;3(3):1377–1397. DOI: 10.3390/polym3031377
10. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. *Nature Medicine*. 2013;19(12):1584–1596. DOI: 10.1038/nm.3407
11. Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO. Tight junctions at the blood-brain barrier. *Frontiers in Physiology*. 2012;3:81. DOI: 10.3389/fphys.2012.00081
12. Löscher W, Potschka H. Blood-brain barrier active efflux transporters. *Nature Reviews Neuroscience*. 2005;6(8):591–602. DOI: 10.1038/nrn1729
13. Patel MM, Patel BM. Crossing the blood-brain barrier. *CNS Drugs*. 2017;31(2):109–133. DOI: 10.1007/s40263-016-0405-9
14. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) devices. *Biomaterials*. 2000;21(23):2475–2490. DOI: 10.1016/S0142-9612(00)00115-0
15. Bala I, Hariharan S, Kumar MNVR. PLGA nanoparticles in drug delivery. *Critical Reviews in Therapeutic Drug Carrier Systems*. 2004;21(5):387–422. DOI: 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
16. Jyothi NVN, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS, Srawan GY. Microencapsulation techniques and applications. *Journal of Microencapsulation*. 2010;27(3):187–197. DOI: 10.3109/02652040903131301
17. Dubey R, Shami TC, Bhasker Rao KU. Microencapsulation technology and applications. *Defence Science Journal*. 2009;59(1):82–95. DOI: 10.14429/dsj.59.1487
18. Anal AK, Stevens WF. Chitosan-alginate multilayer beads. *International Journal of Pharmaceutics*. 2005;290(1-2):45–54. DOI: 10.1016/j.ijpharm.2004.11.015
19. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. *Advanced Drug Delivery Reviews*. 2012;64:72–82. DOI: 10.1016/j.addr.2012.09.004
20. Varde NK, Pack DW. Microspheres for controlled release drug delivery. *Expert Opinion on Biological Therapy*. 2004;4(1):35–51. DOI: 10.1517/14712598.4.1.35
21. Jalil R, Nixon JR. Microencapsulation using solvent evaporation technique. *Journal of Microencapsulation*. 1990;7(3):297–325. DOI: 10.3109/02652049009021874
22. Vehring R. Pharmaceutical particle engineering via spray drying. *Pharmaceutical Research*. 2008;25(5):999–1022. DOI: 10.1007/s11095-007-9475-1
23. Thies C. Microencapsulation by coacervation. *Microencapsulation: Processes and Applications*. 1995;1:1–20.
24. George M, Abraham TE. Polyionic hydrocolloids for drug delivery. *Journal of Controlled Release*. 2006;114(1):1–14. DOI: 10.1016/j.jconrel.2006.04.017
25. Arshady R. Microspheres and microcapsules by emulsion polymerization. *Journal of Microencapsulation*. 1990;7(1):1–19. DOI: 10.3109/02652049009021744
26. Arora R, Kuhad A, Kaur IP. Nanoencapsulated donepezil delivery. *International Journal of Pharmaceutics*. 2015;495(1):427–438. DOI: 10.1016/j.ijpharm.2015.08.08
27. Garbayo E, Ansorena E, Lanciego JL, Blanco-Prieto MJ, Aymerich MS. Sustained dopamine delivery systems. *Journal of Controlled Release*. 2013;169(1-2):14–27. DOI: 10.1016/j.jconrel.2013.03.009

28. Patel RB, Carlson AN, Solorio L, Exner AA. Controlled-release anticonvulsant systems. *Drug Development and Industrial Pharmacy*. 2010;36(3):307–317. DOI: 10.3109/03639040903166087

29. Menei P, Benoit JP. Biodegradable microspheres for brain tumor therapy. *Advanced Drug Delivery Reviews*. 2009;61(7-8):580–592. DOI: 10.1016/j.addr.2009.01.003

30. Kaur G, Gupta V. Controlled-release systems for antidepressants. *Drug Delivery Letters*. 2012;2(2):90–98. DOI: 10.2174/221030312800166087

31. Ventola CL. The nanomedicine revolution. *Pharmacy and Therapeutics*. 2012;37(9):512–525.

32. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers. *Nature Materials*. 2013;12(11):991–1003. DOI: 10.1038/nmat3776

33. Illum L. Nasal drug delivery to the brain. *Journal of Pharmacology and Experimental Therapeutics*. 2000;295(1):1–4.

34. Hanson LR, Frey WH. Intranasal delivery bypassing the blood-brain barrier. *BMC Neuroscience*. 2008;9(Suppl 3):S5. DOI: 10.1186/1471-2202-9-S3-S5

35. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in pharmaceutical formulation development. *Drug Discovery Today*. 2021;26(1):80–93. DOI: 10.1016/j.drudis.2020.10.010

36. Tiwari G, Tiwari R, Bannerjee S, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: An updated review. *International Journal of Pharmaceutical Investigation*. 2012;2(1):2–11. DOI: 10.4103/2230-973X.96920

37. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines. *Pharmaceutical Research*. 2016;33(10):2373–2387. DOI: 10.1007/s11095-016-1958-z

38. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles. *Colloids and Surfaces B: Biointerfaces*. 2010;75(1):1–18. DOI: 10.1016/j.colsurfb.2009.09.001

39. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. *ACS Nano*. 2009;3(1):16–20. DOI: 10.1021/nn900002m

40. Couvreur P, Vauthier C. Nanotechnology in drug delivery. *Pharmaceutical Research*. 2006;23(7):1417–1450. DOI: 10.1007/s11095-006-0284-8